Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Inclusion Criteria:

1. Adult patients (≥ 18 years old) with active cancer, defined as cancer (other thanlocalized non-melanoma skin cancer) diagnosed or treated within 6 months, or thepresence of metastatic, recurrent, or progressive malignancy, ongoing anticancertherapy, or hematological malignancy not in complete remission.

2. Objectively confirmed catheter-related upper extremity DVT and treated with anystandard therapeutic anticoagulation (including LMWH dose reduction to 75% after thefirst month) for at least 3 months.

3. Able and willing to provide informed consent.

Exclusion Criteria:

1. Active bleeding or other reasons for which anticoagulation is contraindicated.

2. Other indications requiring ongoing therapeutic dose of anticoagulation as deemednecessary by treating physicians (such as atrial fibrillation, mechanical heartvalve, etc.).

3. Anticoagulation has been permanently stopped or reduced to prophylactic dose priorto enrollment for any reasons, except for participants who were transitioned toapixaban dosing regimen consistent with the protocol (2.5 mg twice daily) for ≤ 3days .

4. Known contraindication for apixaban, such as allergy, hypersensitivity, orpregnancy.

5. Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 (enzyme) and P-glycoprotein.